Pharma BD Deal Intelligence

Metagenomi, Inc. / Acuitas Therapeutics, Inc.

2025 · Licensing/Option · Complete

Metagenomi entered a non-exclusive license agreement with Acuitas Therapeutics under which Acuitas granted Metagenomi rights to certain Acuitas lipid nanoparticle technology, including LNP patents, formulation processes and analytical characterization methods, for manufacturing products incorporating Metagenomi's proprietary genome editing constructs. Financial terms were not disclosed. Disclosed in a Form 8-K filed 1 October 2025.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals